Congratulations to Think Bioscience on closing their oversubscribed $55M Series A round. This milestone underscores the growing recognition of ThinkBio’s synthetic biology platform for uncovering novel pockets on historically undruggable targets and advancing small molecules toward life-changing therapies.
In 2025, Think Bioscience and CrystalsFirst expanded their multi-target collaboration following the discovery of novel mechanisms of action and accelerated structural insights for challenging targets. We’re excited that this momentum continues and that our MAGNET platform contributes to structure-guided design and advancing of novel therapeutics.
We’re happy to celebrate this achievement with the Think Bioscience team and look forward to the next chapter together!
ABOUT Think Bioscience
Think Bioscience is a privately held small molecule discovery company based in Boulder, Colorado, focused on developing therapeutics against targets that have historically been considered “undruggable”. The company’s proprietary platform combines applied microbiology, enzymology, and data science to program microbes to discover novel functional binding pockets. By unveiling novel mechanisms of biomolecular engagement, Think Bioscience’s approach enables the discovery of first-in-class programs for diseases with high unmet need. For more information, please visit: thinkbioscience.com
Dr. Serghei Glinca
CEO, CrystalsFirst GmbH
serghei.glinca@crystalsfirst.com
Philip Jeng
COO, Think Bioscience
pjeng@thinkbioscience.com
Subscribe to stay tuned